| Product Name | Octreotide |
| Synonyms | Sandostatin, SMS 201-995, Longastatin; Octreotide Acetate (CAS 79517-01-4) |
| CAS Number | 83150-76-9 (free base); acetate salt 79517-01-4 |
| Sequence (3-Letter) | H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol (cyclic Cys2–Cys7 disulfide) |
| Sequence (1-Letter) | fCFwKTC-Thr-ol (Cys2–Cys7 disulfide; f = D-Phe, w = D-Trp; C-terminal threoninol) |
| Molecular Formula | C₄₉H₆₆N₁₀O₁₀S₂ |
| Molecular Weight | 1019.24 (free base) |
| Category | Drug Peptide – Somatostatin Analog |
| Purity | ≥98% (by HPLC) |
| Appearance | White to off-white powder |
| Counter Ion | Acetate (supplied as the acetate salt; free base available on request) |
| Peptide Content | ≥80% (per specification) |
| Solubility | Soluble in water and dilute acetic acid |
| Storage | -20°C, desiccated, protected from light |
| Available Scale | mg – kg (research quantities to scale-up batches) |
| QC Documentation | COA, HPLC, MS identity (additional API/regulatory documentation on request) |
| Usage | For research and pharmaceutical development use, and as a reference standard or active pharmaceutical ingredient for manufacturing. Not for human or veterinary use; not for sale to patients. Any therapeutic use is subject to applicable regulatory approval. |
Octreotide is a synthetic cyclic octapeptide and a somatostatin analog, known as a medicine under the brand name Sandostatin (CAS 83150-76-9; acetate salt 79517-01-4). Its sequence is H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol, closed by a disulfide bridge, with a threoninol at the C-terminus. We supply it as a white powder for research and pharmaceutical development.
Octreotide mimics the natural hormone somatostatin but is more potent and longer-acting. It binds somatostatin receptors, mainly the sst2 and sst5 subtypes, and through them suppresses the release of several hormones, including growth hormone, glucagon, insulin, and gut hormones such as gastrin and VIP. Its plasma half-life is far longer than that of natural somatostatin.
Clinically, octreotide is used in acromegaly and in the control of symptoms from certain neuroendocrine tumours, such as the diarrhoea and flushing of carcinoid syndrome and the effects of VIPomas. This is background information only; the material we supply is for research and pharmaceutical manufacturing use, and is not for human or veterinary use and not for sale to patients.
We supply Octreotide with a certificate of analysis, HPLC purity data, and mass-spec identity confirmation. Additional documentation for API and regulatory work is available on request, and salt form and purity can be set to your specification.
Yes. We manufacture Octreotide in-house and supply from research quantities up to scale-up batches. Contact us with your required purity, salt form, and quantity for a quote.
Octreotide is a synthetic cyclic octapeptide and a somatostatin analog, known as a medicine under the brand name Sandostatin. It mimics the natural hormone somatostatin but is more potent and far longer-acting. We supply it as a raw material for research and pharmaceutical development.
Octreotide is an eight-residue peptide with the sequence H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol. It is cyclised by a disulfide bridge between the two cysteine residues, carries D-phenylalanine and D-tryptophan, and ends in a threoninol, an amino alcohol, rather than a normal carboxyl terminus. These features make it stable and long-acting. Its free-base CAS number is 83150-76-9 (acetate salt 79517-01-4), its molecular formula is C49H66N10O10S2, and its molecular weight is about 1019.
Octreotide is an agonist at somatostatin receptors, binding mainly the sst2 and sst5 subtypes. Through these receptors it suppresses the release of growth hormone and of several other hormones, including glucagon, insulin, gastrin, and vasoactive intestinal peptide. It reproduces the inhibitory actions of natural somatostatin, but where natural somatostatin lasts only minutes in the blood, octreotide acts for a couple of hours, which is why it became a practical long-acting analog.
Octreotide is used clinically in acromegaly and to control symptoms of certain neuroendocrine tumours, including the diarrhoea and flushing of carcinoid syndrome and the effects of VIPomas. This information is provided as scientific and reference background only. The material supplied by SynPeptide is intended for research and pharmaceutical manufacturing, is not for human or veterinary use, and is not for sale to patients; any therapeutic use is subject to applicable regulatory approval.
We supply Octreotide with a certificate of analysis, HPLC purity data, and mass-spectrometry identity confirmation, with further documentation available to support active pharmaceutical ingredient and regulatory work. Purity, salt form, and counter-ion can be set to your specification for use as a reference standard or in process development.
We manufacture Octreotide by solid-phase synthesis, including the disulfide cyclisation, the D-amino acid residues, and the C-terminal threoninol, and supply it from research quantities through to scale-up batches. For related capabilities, see drug peptides, custom peptide synthesis, peptide modification, and cyclic peptides. Material is supplied for research and pharmaceutical manufacturing use only.
